In this edition:
Differential response with nodal metastases in mHSPC
8-month PSA predicts outcomes in mCSPC
Cabazitaxel every 2 weeks vs 3 weeks in older mCRPC patients
CYP11A1 blocker in metastatic castration-resistant prostate cancer
Enfortumab vedotin + pembrolizumab for metastatic urothelial cancer
Intensification of ADT for high-risk biochemically relapsed prostate cancer
Enzalutamide + metformin for metastatic castration-resistant prostate cancer
Outcomes of relapsed clinical stage I vs de novo metastatic testicular cancer
Outcomes after neoadjuvant chemotherapy in basal/squamous tumours
Please login below to download this issue (PDF)